Bayer Secures €3.0 Billion to Strengthen Capital Structure

Bayer Aktiengesellschaft has announced securing €3.0 billion in equity capital aimed at improving its capital structure. This funding comes via a new agreement with Apollo, a global asset management firm. Under this arrangement, Apollo-managed funds and affiliates will acquire a minority, non-controlling stake in a newly created entity focused on Bayer's long-acting reversible contraceptives (LARC) business. Bayer will maintain a majority stake and operational control over this entity, ensuring no changes to its LARC strategy or activities.

This transaction enhances Bayer's financial flexibility amidst increased liquidity needs related to bond maturities and litigation processes. The company remains committed to executing its long-term strategic priorities without altering the core aspects of their pharmaceutical division's operations. Antitrust authorities' approval is awaited, with transaction completion anticipated in Q3 2026.